Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

• Main Authors: Chia-Jung Li, Li-Te Lin, Pei-Yi Chu, An-Jen Chiang, Hsiao-Wen Tsai, Yi-Han Chiu, Mei-Shu Huang, Zhi-Hong Wen, Kuan-Hao Tsui
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Journal of Personalized Medicine
• Subjects: ovarian cancer; bioinformatics; CREB1; drug perturbation
• Online Access: https://www.mdpi.com/2075-4426/11/4/316

This paper investigates the expression of the CREB1 gene in ovarian cancer (OV) by deeply excavating the gene information in the multiple databases and the mechanism thereof. In short, we found that the expression of the CREB1 gene in ovarian cancer tissue was significantly higher than that of normal ovarian tissue. Kaplan–Meier survival analysis showed that the overall survival was significantly shorter in patients with high expression of the CREB1 gene than those in patients with low expression of the CREB1 gene, and the prognosis of patients with low expression of the CREB1 gene was better. The CREB1 gene may play a role in the occurrence and development of ovarian cancer by regulating the process of protein. Based on differentially expressed genes, 20 small-molecule drugs that potentially target CREB1 with abnormal expression in OV were obtained from the CMap database. Among these compounds, we found that naloxone has the greatest therapeutic value for OV. The high expression of the CREB1 gene may be an indicator of poor prognosis in ovarian cancer patients. Targeting CREB1 may be a potential tool for the diagnosis and treatment of OV.